Advertisement

Topics

A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.

2015-05-26 21:58:48 | BioPortfolio

Published on BioPortfolio: 2015-05-26T21:58:48-0400

Clinical Trials [4671 Associated Clinical Trials listed on BioPortfolio]

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

The purpose of this study is to determine if combination Erlotinib, Cisplatin/Carboplatin, and Paclitaxel are effective first line treatment for metastatic, recurrent and persistent squamo...

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

The main purpose of this research study is to collect information to learn how effective erlotinib (tarceva) is in combination with either bevacizumab or sulindac in treating patients with...

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

The goal of this clinical research study is to learn if RAD001 in combination with Tarceva (erlotinib hydrochloride) can help to control HNSCC. The safety of this drug combination will al...

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treati...

PubMed Articles [41873 Associated PubMed Articles listed on BioPortfolio]

Economic evaluation of a person-centred care intervention in head and neck oncology: results from a randomized controlled trial.

Head and neck cancer and its treatment deteriorate quality of life, but symptoms improve with person-centred care. We examined the cost-effectiveness of a person-centred care intervention versus stand...

Association of the Patient Protection and Affordable Care Act With Insurance Coverage for Head and Neck Cancer in the SEER Database.

Patients with head and neck squamous cell cancer (HNSCC) are often uninsured or underinsured at the time of their diagnosis. This access to care has been shown to influence treatment decisions and sur...

Head and Neck Masses.

Head and neck cancers comprise 4% of the cancer burden in the United States each year. Many types of head and neck cancers present as an asymptomatic, nontender neck mass or nonspecific symptoms, such...

Suppression of SESN1 reduces cisplatin and hyperthermia resistance through increasing reactive oxygen species (ROS) in human maxillary cancer cells.

Cisplatin is used as a standard chemotherapeutic agent for head and neck cancer treatment. However, some head and neck cancers have cisplatin resistance, leading to difficulty in treatment and poor pr...

Progress in the study of artemisinin and its derivatives against head and neck cancer.

The head and neck cancer is one of the most common malignant tumors in the world. There are more than 600 000 new cases in the world every year. Cisplatin is often used in the treatment of head and ne...

Medical and Biotech [MESH] Definitions

Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)

A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.

Dissection in the neck to remove all disease tissues including cervical LYMPH NODES and to leave an adequate margin of normal tissue. This type of surgery is usually used in tumors or cervical metastases in the head and neck. The prototype of neck dissection is the radical neck dissection described by Crile in 1906.

A form of RHABDOMYOSARCOMA arising primarily in the head and neck, especially the orbit, of children below the age of 10. The cells are smaller than those of other rhabdomyosarcomas and are of two basic cell types: spindle cells and round cells. This cancer is highly sensitive to chemotherapy and has a high cure rate with multi-modality therapy. (From Holland et al., Cancer Medicine, 3d ed, p2188)

Institutions specializing in the care of cancer patients.

More From BioPortfolio on "A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer."

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial